Patients seeking semaglutide-based weight loss treatment will likely need to rely on branded medications or other approved therapies
Tirzepatide, however, is a dual agonist
Researchers study it for Excess body weight, weight-related risk, type 2 diabetes, sleep apnea, knee osteoarthritis pain, and other weight-related health problems
Some people spend six to eight weeks at doses like 10 mg or 12.5 mg before deciding whether to continue higher
It was approved in the UK in 2023 for weight management in adults with: BMI 30 kg/m (obesity), or BMI 27 kg/m (overweight) with at least one weight-related condition The medication works through several mechanisms: Reduces hunger signals by acting on the brains appetite control centre Slows stomach emptying , creating longer-lasting fullness after meals Reduces food cravings , particularly for ultra-processed foods Improves blood sugar control by enhancing insulin function Clinical trials show that people taking Wegovy lose an average of 15% of their body weight after 68 weeks, compared to 2.4% with placebo